No benefit found for use of probiotic Bifidobacterium breve to prevent death, late-onset sepsis
The results of a phase 3 randomised controlled trial, published today in The Lancet, show that, despite being safe to administer, there is no benefit in using the probiotic Bifidobacterium breve (BBG-001) to prevent late-onset ...
Nov 26, 2015
0
1